Free Trial

Invivyd (IVVD) Competitors

Invivyd logo
$1.43 +0.20 (+16.26%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IVVD vs. AQST, ESPR, IVA, RAPP, CYRX, ZVRA, PRME, BCYC, EOLS, and REPL

Should you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

Invivyd vs. Its Competitors

Invivyd (NASDAQ:IVVD) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Invivyd has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Invivyd presently has a consensus target price of $3.18, indicating a potential upside of 122.61%. Aquestive Therapeutics has a consensus target price of $10.29, indicating a potential upside of 103.68%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts plainly believe Invivyd is more favorable than Aquestive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivyd
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Aquestive Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 25.4% of Invivyd shares are owned by company insiders. Comparatively, 8.4% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aquestive Therapeutics has higher revenue and earnings than Invivyd. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invivyd$25.38M6.77-$169.93M-$0.92-1.55
Aquestive Therapeutics$44.13M11.41-$44.14M-$0.70-7.21

Aquestive Therapeutics has a net margin of -147.38% compared to Invivyd's net margin of -238.33%. Aquestive Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.

Company Net Margins Return on Equity Return on Assets
Invivyd-238.33% -177.89% -90.96%
Aquestive Therapeutics -147.38%N/A -63.87%

In the previous week, Aquestive Therapeutics had 15 more articles in the media than Invivyd. MarketBeat recorded 18 mentions for Aquestive Therapeutics and 3 mentions for Invivyd. Aquestive Therapeutics' average media sentiment score of 0.91 beat Invivyd's score of 0.30 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Invivyd
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aquestive Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Aquestive Therapeutics beats Invivyd on 11 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVVD vs. The Competition

MetricInvivydMED IndustryMedical SectorNASDAQ Exchange
Market Cap$147.78M$3.20B$5.87B$10.14B
Dividend YieldN/A2.30%5.68%4.59%
P/E Ratio-1.5521.1774.5225.93
Price / Sales6.77480.02549.78198.13
Price / CashN/A46.6837.5660.44
Price / Book2.559.6112.166.29
Net Income-$169.93M-$53.29M$3.28B$270.77M
7 Day Performance25.44%0.28%0.87%3.88%
1 Month Performance80.33%5.73%4.96%4.88%
1 Year Performance24.35%10.52%60.74%26.01%

Invivyd Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVVD
Invivyd
3.522 of 5 stars
$1.43
+16.3%
$3.18
+122.6%
+24.3%$147.78M$25.38M-1.55100Short Interest ↑
AQST
Aquestive Therapeutics
2.2446 of 5 stars
$5.01
-7.6%
$10.29
+105.3%
+11.0%$540.50M$57.56M-7.16160Gap Down
ESPR
Esperion Therapeutics
4.1054 of 5 stars
$2.51
-6.3%
$7.00
+178.9%
+62.3%$540.35M$332.31M-5.12200Positive News
IVA
Inventiva
3.154 of 5 stars
$5.37
-3.6%
$14.83
+176.2%
+149.3%$532.84M$9.95M0.00100Positive News
Short Interest ↑
Gap Down
RAPP
Rapport Therapeutics
2.6713 of 5 stars
$31.47
+119.2%
$31.00
-1.5%
+25.6%$524.11MN/A-12.59N/ATrending News
Analyst Upgrade
Insider Trade
Gap Up
High Trading Volume
CYRX
CryoPort
3.7821 of 5 stars
$10.04
-3.0%
$12.00
+19.5%
+4.3%$518.19M$228.38M7.551,186Positive News
Insider Trade
ZVRA
Zevra Therapeutics
2.7093 of 5 stars
$8.33
-6.9%
$23.71
+184.7%
+2.1%$502.41M$23.61M-39.6720Analyst Downgrade
PRME
Prime Medicine
3.2813 of 5 stars
$3.89
+4.6%
$8.92
+129.2%
+0.5%$500.62M$4.96M-1.90234
BCYC
Bicycle Therapeutics
3.6263 of 5 stars
$7.00
-2.2%
$22.22
+217.5%
-74.0%$495.86M$35.28M-1.99240Positive News
EOLS
Evolus
4.1962 of 5 stars
$7.61
-0.7%
$21.25
+179.2%
-56.3%$495.49M$266.27M-7.77170Positive News
Short Interest ↓
REPL
Replimune Group
3.9175 of 5 stars
$6.04
-4.6%
$6.50
+7.6%
-44.8%$494.09MN/A-1.86210Trending News

Related Companies and Tools


This page (NASDAQ:IVVD) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners